Common Bacterial Infections in Persons Who Inject Drugs
Abstract
:1. Introduction
2. Barriers to Successful Outcomes
3. Disparities in Antimicrobial Team Resources
3.1. Lack of Access to Addiction Medicine Specialists
3.2. Outpatient Parenterial Antimicrobial Therapy Hesitancy
3.3. Opioid Impact on Immune Response
3.4. Changing Approach to Management of Infection
4. Available Therapies That May Improve Outcomes/Compliance
4.1. Long-Acting Glycopeptides
4.2. Oxazolidinones
4.3. Other Oral Agents
5. Conclusions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Understanding the Epidemic. CDC Opioid Overdose. 2021. Available online: https://www.cdc.gov/drugoverdose/epidemic/index.html (accessed on 25 May 2021).
- Lansky, A.; Finlayson, T.; Johnson, C.; Holtzman, D.; Wejnert, C.; Mitsch, A.; Gust, D.; Chen, R.; Mizuno, Y.; Crepaz, N. Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS ONE 2014, 9, e97596. [Google Scholar] [CrossRef]
- Østerdal, O.B.; Salminen, P.-R.; Jordal, S.; Sjursen, H.; Wendelbo, Ø.; Haaverstad, R. Cardiac surgery for infective endocarditis in patients with intravenous drug use. Interact. Cardiovasc. Thorac. Surg. 2016, 22, 633–640. [Google Scholar] [CrossRef] [PubMed]
- Thalme, A.; Westling, K.; Julander, I. In-hospital and long-term mortality in infective endocarditis in injecting drug users compared to non-drug users: A retrospective study of 192 episodes. Scand. J. Infect. Dis. 2007, 39, 197–204. [Google Scholar] [CrossRef] [PubMed]
- Rabkin, D.G.; Mokadam, N.A.; Miller, D.W.; Goetz, R.R.; Verrier, E.D.; Aldea, G.S. Long-term outcome for the surgical treatment of infective endocarditis with a focus on intravenous drug users. Ann. Thorac. Surg. 2012, 93, 51–57. [Google Scholar] [CrossRef]
- Biancarelli, D.L.; Biello, K.B.; Childs, E.; Drainoni, M.; Salhaney, P.; Edeza, A.; Mimiaga, M.J.; Saitz, R.; Bazzi, A.R. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019, 198, 80–86. [Google Scholar] [CrossRef]
- Serota, D.P.; Niehaus, E.D.; Schechter, M.C.; Jacob, J.T.; Jones, J.; Ray, S.M.; Kelley, C.F.; Kempker, R.R. Disparity in quality of infectious disease vs addiction care among patients with injection drug use–associated staphylococcus aureus bacteremia. Open Forum Infect. Dis. 2019, 6, ofz289. [Google Scholar] [CrossRef]
- Bearnot, B.; Mitton, J.A.; Hayden, M.; Park, E.R. Experiences of care among individuals with opioid use disorder-associated endocarditis and their healthcare providers: Results from a qualitative study. J. Subst. Abus. Treat. 2019, 102, 16–22. [Google Scholar] [CrossRef]
- Kim, J.-H.; Fine, D.R.; Li, L.; Kimmel, S.D.; Ngo, L.H.; Suzuki, J.; Price, C.N.; Ronan, M.V.; Herzig, S.J. Disparities in United States hospitalizations for serious infections in patients with and without opioid use disorder: A nationwide observational study. PLOS Med. 2020, 17, e1003247. [Google Scholar] [CrossRef]
- Sulzgruber, P.; Schnaubelt, S.; Koller, L.; Laufer, G.; Pilz, A.; Kazem, N.; Winter, M.-P.; Steinlechner, B.; Andreas, M.; Fleck, T.; et al. An extended duration of the pre-operative hospitalization is associated with an increased risk of healthcare-associated infections after cardiac surgery. Sci. Rep. 2020, 10, 8006. [Google Scholar] [CrossRef]
- Yong, T.Y.; Fok, J.S.; Hakendorf, P.; Ben-Tovim, D.; Thompson, C.H.; Li, J.Y. Characteristics and outcomes of discharges against medical advice among hospitalised patients. Intern. Med. J. 2013, 43, 798–802. [Google Scholar] [CrossRef]
- Larney, S.; Peacock, A.; Mathers, B.M.; Hickman, M.; Degenhardt, L. A systematic review of injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend. 2017, 171, 39–49. [Google Scholar] [CrossRef] [PubMed]
- Lewis, R.; Baugher, A.R.; Finlayson, T.; Wejnert, C.; Sionean, C. Healthcare access and utilization among persons who inject drugs in medicaid expansion and nonexpansion states: 22 united states cities, 2018. J. Infect. Dis. 2020, 222, S420–S428. [Google Scholar] [CrossRef] [PubMed]
- Olea, A.; Grochowski, J.; Luetkemeyer, A.F.; Robb, V.; Saberi, P. Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection. Integr. Pharm. Res. Pract. 2018, 7, 105–111. [Google Scholar] [CrossRef] [PubMed]
- Fleming-Dutra, K.E.; Hersh, A.L.; Shapiro, D.J.; Bartoces, M.; Enns, E.A.; File, T.M., Jr.; Finkelstein, J.A.; Gerber, J.S.; Hyun, D.Y.; Linder, J.A.; et al. Prevalence of inappropriate antibiotic prescriptions among us ambulatory care visits, 2010–2011. JAMA 2016, 315, 1864–1873. [Google Scholar] [CrossRef]
- Baggs, J.; Fridkin, S.K.; Pollack, L.A.; Srinivasan, A.; Jernigan, J.A. Estimating national trends in inpatient antibiotic use among us hospitals from 2006 to 2012. JAMA Intern. Med. 2016, 176, 1639–1648. [Google Scholar] [CrossRef]
- Fridkin, S.; Baggs, J.; Fagan, R.; Magill, S.; Pollack, L.A.; Malpiedi, P.; Slayton, R.; Khader, K.; Rubin, M.A.; Jones, M.; et al. Vital signs: Improving antibiotic use among hospitalized patients. MMWR Morb. Mortal. Wkly. Rep. 2014, 63, 194–200. [Google Scholar]
- Rosenthal, E.S.; Karchmer, A.W.; Theisen-Toupal, J.; Castillo, R.A.; Rowley, C.F. Suboptimal addiction interventions for patients hospitalized with injection drug use-associated infective endocarditis. Am. J. Med. 2015, 129, 481–485. [Google Scholar] [CrossRef]
- Marks, L.R.; Munigala, S.; Warren, D.K.; Liang, S.Y.; Schwarz, E.S.; Durkin, M.J. Addiction medicine consultations reduce readmission rates for patients with serious infections from opioid use disorder. Clin. Infect. Dis. 2019, 68, 1935–1937. [Google Scholar] [CrossRef]
- Tan, C.; Shojaei, E.; Wiener, J.; Shah, M.; Koivu, S.; Silverman, M. Risk of new bloodstream infections and mortality among people who inject drugs with infective endocarditis. JAMA Netw. Open 2020, 3, e2012974. [Google Scholar] [CrossRef]
- Chang, H.-Y.; Daubresse, M.; Saloner, B.; Alexander, G.C. Chronic disease medication adherence after initiation of buprenorphine for opioid use disorder. Med. Care 2019, 57, 667–672. [Google Scholar] [CrossRef]
- MacKenzie, M.; Rae, N.; Nathwani, D. Outcomes from global adult outpatient parenteral antimicrobial therapy programmes: A review of the last decade. Int. J. Antimicrob. Agents 2014, 43, 7–16. [Google Scholar] [CrossRef] [PubMed]
- Suzuki, J.; Johnson, J.; Montgomery, M.; Hayden, M.; Price, C. Outpatient parenteral antimicrobial therapy among people who inject drugs: A review of the literature. Open Forum Infect. Dis. 2018, 5, ofy194. [Google Scholar] [CrossRef] [PubMed]
- Handbook of Outpatient Parenteral Antimicrobial Therapy for Infectious Diseases 3rd Edition. Infectious Diseases Society of America. 2016. Available online: https://www.idsociety.org/globalassets/bb-complex-pages/idsa/opat-ehandbook/opat_epub_finalv2.pdf (accessed on 25 May 2021).
- Beieler, A.; Magaret, A.; Zhou, Y.; Schleyer, A.; Wald, A.; Dhanireddy, S. Outpatient parenteral antimicrobial therapy in vulnerable populations— people who inject drugs and the homeless. J. Hosp. Med. 2019, 14, 105–109. [Google Scholar] [CrossRef]
- Eaton, E.F.; Mathews, R.E.; Lane, P.S.; Paddock, C.S.; Rodriguez, J.M.; Taylor, B.B.; Saag, M.S.; Kilgore, M.L.; A Lee, R. A 9-point risk assessment for patients who inject drugs and require intravenous antibiotics: Focusing inpatient resources on patients at greatest risk of ongoing drug use. Clin. Infect. Dis. 2019, 68, 1041–1043. [Google Scholar] [CrossRef]
- Liang, X.; Liu, R.; Chen, C.; Ji, F.; Li, T. Opioid system modulates the immune function: A review. Transl. Perioper. Pain. Med. 2016, 1, 5–13. [Google Scholar]
- Baddour, L.M.; Wilson, W.R.; Bayer, A.S.; Fowler, V.G., Jr.; Tleyjeh, I.M.; Rybak, M.J.; Barsic, B.; Lockhart, P.B.; Gewitz, M.H.; Levison, M.E.; et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 2015, 132, 1435–1486. [Google Scholar] [CrossRef]
- Habib, G.; Lancellotti, P.; Antunes, M.J.; Bongiorni, M.G.; Casalta, J.-P.; Zotti, F.D.; Dulgheru, R.; Khoury, G.E.I.; Erba, P.A.; Lung, B.; et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur. Heart J 2015, 36, 3075–3128. [Google Scholar]
- Osmon, D.R.; Berbari, E.F.; Berendt, A.R.; Lew, D.; Zimmerli, W.; Steckelberg, J.M.; Rao, N.; Hanssen, A.; Wilson, W.R. Diagnosis and management of prosthetic joint infection: Clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 2013, 56, e1–e25. [Google Scholar] [CrossRef]
- Conterno, L.O.; Turchi, M.D. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst. Rev. 2013, 2013, CD004439. [Google Scholar] [CrossRef]
- Nelson, A.N.; Justo, J.A.; Bookstaver, P.B.; Kohn, J.; Albrecht, H.; Al-Hasan, M.N. Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections. Infection 2017, 45, 613–620. [Google Scholar] [CrossRef]
- Punjabi, C.; Tien, V.; Meng, L.; Deresinski, S.; Holubar, M. Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. ß-lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis. Open Forum Infect. Dis. 2019, 6, ofz364. [Google Scholar] [PubMed]
- Mermel, L.A.; Allon, M.; Bouza, E.; Craven, D.E.; Flynn, P.; O’Grady, N.P.; Raad, I.I.; Rijnders, B.J.A.; Sherertz, R.J.; Warren, D.K. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2009, 49, 1–45. [Google Scholar] [CrossRef] [PubMed]
- Iversen, K.; Ihlemann, N.; Gill, S.U.; Madsen, T.; Elming, H.; Jensen, K.T.; Bruun, N.E.; Høfsten, D.E.; Fursted, K.; Christensen, J.J.; et al. Partial oral versus intravenous antibiotic treatment of endocarditis. New Engl. J. Med. 2019, 380, 415–424. [Google Scholar] [CrossRef]
- Li, H.-K.; Rombach, I.; Zambellas, R.; Walker, A.S.; McNally, M.A.; Atkins, B.L.; Lipsky, B.A.; Hughes, H.C.; Bose, D.; Kümin, M.; et al. Oral versus intravenous antibiotics for bone and joint infection. N. Engl. J. Med. 2019, 380, 425–436. [Google Scholar] [CrossRef]
- Yahav, D.; Franceschini, E.; Koppel, F.; Turjeman, A.; Babich, T.; Bitterman, R.; Neuberger, A.; Ghanem-Zoubi, N.; Santoro, A.; Eliakim-Raz, N.; et al. Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial. Clin. Infect. Dis. 2019, 69, 1091–1098. [Google Scholar] [CrossRef]
- Jamil, M.; Sultan, I.; Gleason, T.G.; Navid, F.; Fallert, M.A.; Suffoletto, M.S.; Kilic, A. Infective endocarditis: Trends, surgical outcomes, and controversies. J. Thorac. Dis. 2019, 11, 4875–4885. [Google Scholar] [CrossRef]
- Kaiser, S.P.; Melby, S.J.; Zierer, A.; Schuessler, R.B.; Moon, M.R.; Moazami, N.; Pasque, M.K.; Huddleston, C.; Damiano, R.J.; Lawton, J.S. Long-term outcomes in valve replacement surgery for infective endocarditis. Ann. Thorac. Surg. 2007, 83, 30–35. [Google Scholar] [CrossRef]
- Tong, S.Y.C.; Lye, D.C.; Yahav, D.; Sud, A.; Robinson, J.O.; Nelson, J.; Archuleta, S.; Roberts, M.A.; Cass, A.; Paterson, D.L.; et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia relapse, or treatment failure in patients with MRSA bacteremia a randomized clinical trial. JAMA 2020, 323, 527–537. [Google Scholar] [CrossRef]
- Lodise, T.P.; Rosenkranz, S.L.; Finnemeyer, M.; Evans, S.; Sims, M.; Zervos, M.J.; Creech, C.B.; Patel, P.C.; Keefer, M.; Riska, P.; et al. The emperor’s new clothes: PRospective Observational evaluation of the association between initial vancomycin exposure and failure rates among aDult hospitalizEd patients with methicillin-resistant staphylococcus aureus bloodstream infections (PROVIDE). Clin. Infect. Dis. 2020, 70, 1536–1545. [Google Scholar] [CrossRef]
- Fowler, V.G.; Boucher, H.W.; Corey, R.; Abrutyn, E.; Karchmer, A.W.; Rupp, M.E.; Levine, D.P.; Chambers, H.F.; Tally, F.P.; Vigliani, G.A.; et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. New Engl. J. Med. 2006, 355, 653–665. [Google Scholar] [CrossRef]
- Seval, N.; Eaton, E.; Springer, S.A. Beyond Antibiotics: A Practical Guide for the Infectious Disease Physician to Treat Opioid Use Disorder in the Setting of Associated Infectious Diseases. Open Forum Infect. Dis. 2019, 7, ofz539. [Google Scholar] [CrossRef] [PubMed]
- Westlake, A.A.; Eisenberg, M.P. Infectious disease (ID) learning unit: What the ID clinician needs to know about buprenorphine treatment for opioid use disorder. Open Forum Infect. Dis. 2017, 4, ofw251. [Google Scholar] [CrossRef] [PubMed]
- Serota, D.P.; Barocas, J.A.; Springer, S.A. Infectious complications of addiction: A call for a new subspecialty within infectious diseases. Clin. Infect. Dis. 2020, 70, 968–972. [Google Scholar] [CrossRef] [PubMed]
- Vyas, D.A.; Marinacci, L.; Sundt, T.; Jassar, A.; Bearnot, B.; Triant, V.A.; Nelson, S.B.; Wakeman, S.E.; Dudzinski, D.M.; Paras, M.L. 709. Multidisciplinary drug use endocarditis team (DUET): Results from an academic center cohort. Open Forum Infect. Dis. 2020, 7, S405–S407. [Google Scholar] [CrossRef]
- Liu, C.; Bayer, A.; Cosgrove, S.E.; Daum, R.S.; Fridkin, S.K.; Gorwitz, R.J.; Kaplan, S.L.; Karchmer, A.W.; Levine, D.P.; Murray, B.E.; et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 2011, 52, e18–e55. [Google Scholar] [CrossRef]
- Andes, D.; Craig, W.A. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob. Agents Chemother. 2007, 51, 1633–1642. [Google Scholar] [CrossRef]
- Sader, H.S.; Mendes, R.E.; Duncan, L.R.; Pfaller, M.A.; Flamm, R.K. Antimicrobial activity of dalbavancin against staphylococcus aureus with decreased susceptibility to glycopeptides, daptomycin, and/or linezolid from u.s. medical centers. Antimicrob. Agents Chemother. 2018, 62, e02397-17. [Google Scholar] [CrossRef]
- Mendes, R.E.; Sader, H.S.; Flamm, R.K.; Farrell, D.J.; Jones, R.N. Oritavancin activity against staphylococcus aureus causing invasive infections in u.s. and european hospitals: A 5-year international surveillance program. Antimicrob. Agents Chemother. 2014, 58, 2921–2924. [Google Scholar] [CrossRef]
- Johnson, J.A.; Feeney, E.R.; Kubiak, D.W.; Corey, G.R. Prolonged Use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis. Open Forum Infect. Dis. 2015, 2, ofv156. [Google Scholar] [CrossRef]
- CLSI. M100 Performance Standards for Antimicrobial Susceptibility Testing, 30th ed.; CLSI Supplement M100; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2020. [Google Scholar]
- Nguyen, J.P.; Contreras, B.X.; Sierra-Hoffman, M.; Saddler, K.; Stevens, M.L.; Castro-Lainez, M.T.; Knox, B.; Deliz, R.J. Successful treatment of a prosthetic hip infection due to Enterococcus faecalis with sequential dosing of oritavancin and prosthesis preservation without prosthetic joint surgical manipulation. IDCases 2020, 22, e00949. [Google Scholar] [CrossRef]
- Delaportas, D.J.; Estrada, S.J.; Darmelio, M. Successful treatment of methicillin susceptible Staphylococcus aureus Osteomyelitis with Oritavancin. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2017, 37, e90–e92. [Google Scholar] [CrossRef]
- Redell, M.; Sierra-Hoffman, M.; Assi, M.; Bochan, M.; Chansolme, D.; Gandhi, A.; Sheridan, K.; Soosaipillai, I.; Walsh, T.; Massey, J. The CHROME study, a real-world experience of single- and multiple-dose oritavancin for treatment of Gram-positive infections. Open Forum Infect. Dis. 2019, 6, ofz479. [Google Scholar] [CrossRef] [PubMed]
- Rose, W.E.; Hutson, P.R. A two-dose oritavancin regimen using pharmacokinetic estimation analysis. Drugs-Real World Outcomes 2020, 7, 36–40. [Google Scholar] [CrossRef]
- Ahiskali, A.; Rhodes, H. Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs. BMC Pharmacol. Toxicol. 2020, 21, 73. [Google Scholar] [CrossRef]
- Schulz, L.T.; Dworkin, E.; Dela-Pena, J.; Rose, W.E. Multiple-dose oritavancin evaluation in a retrospective cohort of patients with complicated infections. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2018, 38, 152–159. [Google Scholar] [CrossRef]
- Wunsch, S.; Krause, R.; Valentin, T.; Prattes, J.; Janata, O.; Lenger, A.; Bellmann-Weiler, R.; Weiss, G.; Zollner-Schwetz, I. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections. Int. J. Infect. Dis. 2019, 81, 210–214. [Google Scholar] [CrossRef]
- Raad, I.; Darouiche, R.; Vazquez, J.; Lentnek, A.; Hachem, R.; Hanna, H.; Goldstein, B.; Henkel, T.; Seltzer, E. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin. Infect. Dis. 2005, 40, 374–380. [Google Scholar] [CrossRef]
- Tobudic, S.; Forstner, C.; Burgmann, H.; Lagler, H.; Ramharter, M.; Steininger, C.; Vossen, M.; Winkler, S.; Thalhammer, F. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of vienna. Clin. Infect. Dis. 2018, 67, 795–798. [Google Scholar] [CrossRef]
- Hidalgo-Tenorio, C.; Vinuesa, D.; Plata, A.; Dávila, P.M.; Iftimie, S.; Sequera, S.; Loeches, B.; Lopez-Cortés, L.E.; Fariñas, M.C.; Fernández-Roldan, C.; et al. DALBACEN cohort: Dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann. Clin. Microbiol. Antimicrob. 2019, 18, 30. [Google Scholar] [CrossRef]
- Bork, J.T.; Heil, E.L.; Berry, S.; Lopes, E.; Davé, R.; Gilliam, B.L.; Amoroso, A. Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive Gram-positive infections. Infect. Dis. Ther. 2019, 8, 171–184. [Google Scholar] [CrossRef]
- Bryson-Cahn, C.; Beieler, A.M.; Chan, J.D.; Harrington, R.D.; Dhanireddy, S. Dalbavancin as secondary therapy for serious staphylococcus aureus infections in a vulnerable patient population. Open Forum Infect. Dis. 2019, 6, ofz028. [Google Scholar] [CrossRef] [PubMed]
- Ajaka, L.; Heil, E.; Schmalzle, S. Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care. Antibiotics 2020, 9, 700. [Google Scholar] [CrossRef]
- Morrisette, T.; Miller, M.A.; Montague, B.T.; Barber, G.R.; McQueen, R.B.; Krsak, M. Long-acting lipogylcopeptides: “Lineless antibiotics” for serious infections in persons who use drugs. Open Forum Infect. Dis. 2019, 6, ofz274. [Google Scholar] [CrossRef] [PubMed]
- Russo, T.A.; Ritchie, H.R.; Schimmel, J.J.; Lorenzo, M.P. Dalbavancin Use in Persons Who Use Drugs May Increase Adherence Without Increasing Cost. J. Pharm. Technol. 2024, 40, 3–9. [Google Scholar] [CrossRef]
- Lexicomp Online. Dalbavancin; UpToDate, Inc.: Waltham, MA, USA, 2021. [Google Scholar]
- Dunne, M.W.; Puttagunta, S.; Sprenger, C.R.; Rubino, C.; Van Wart, S.; Baldassarre, J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob. Agents Chemother. 2015, 59, 1849–1855. [Google Scholar] [CrossRef]
- Rappo, U.; Puttagunta, S.; Shevchenko, V.; Shevchenko, A.; Jandourek, A.; Gonzalez, P.L.; Suen, A.; Casullo, V.M.; Melnick, D.; Miceli, R.; et al. Dalbavancin for the treatment of osteomyelitis in adult patients: A randomized clinical trial of efficacy and safety. Open Forum Infect. Dis. 2019, 6, ofy331. [Google Scholar] [CrossRef]
- Willekens, R.; Puig-Asensio, M.; Ruiz-Camps, I.; Larrosa, M.N.; González-López, J.J.; Rodríguez-Pardo, D.; Fernández-Hidalgo, N.; Pigrau, C.; Almirante, B. Early oral switch to linezolid for low-risk patients with staphylococcus aureus bloodstream infections: A propensity-matched cohort study. Clin. Infect. Dis. 2019, 69, 381–387. [Google Scholar] [CrossRef]
- Jorgensen, S.C.J.; Lagnf, A.M.; Bhatia, S.; Shamim, M.-D.; Rybak, M.J. Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: One step closer. J. Antimicrob. Chemother. 2019, 74, 489–498. [Google Scholar] [CrossRef]
- Sudhindra, P.; Lee, L.; Wang, G.; Dhand, A. Tedizolid for enterococcal bacteremia. Open Forum. Infect Dis. 2016, 3 (Suppl. 1), 1344. [Google Scholar] [CrossRef]
- Pfizer, Inc. Zyvox (linezolid); Pharmacia and Upjohn: New York, NY, USA, 2021. [Google Scholar]
- Butterfield, J.M.; Lawrence, K.R.; Reisman, A.; Huang, D.B.; Thompson, C.A.; Lodise, T.P. Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: An analysis of Phase III and IV randomized clinical trial data. J. Antimicrob. Chemother. 2012, 67, 494–502. [Google Scholar] [CrossRef]
- Lodise, T.P.; Patel, N.; Rivera, A.; Tristani, L.; Lazariu, V.; Vandewall, H.; McNutt, L.A. Comparative evaluation of serotonin toxicity among veterans affairs patients receiving linezolid and vancomycin. Antimicrob. Agents Chemother. 2013, 57, 5901–5911. [Google Scholar] [CrossRef] [PubMed]
- Crass, R.L.; Cojutti, P.G.; Pai, M.P.; Pea, F. Reappraisal of linezolid dosing in renal impairment to improve safety. Antimicrob. Agents Chemother. 2019, 63, e00605-19. [Google Scholar] [CrossRef] [PubMed]
- Nukui, Y.; Hatakeyama, S.; Okamoto, K.; Yamamoto, T.; Hisaka, A.; Suzuki, H.; Yata, N.; Yotsuyanagi, H.; Moriya, K. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J. Antimicrob. Chemother. 2013, 68, 2128–2133. [Google Scholar] [CrossRef] [PubMed]
- ClinicalTrials.gov. Antibiotic Strategies in People Who Inject Drugs (PWID) with Complicated Infections: A Randomized Clinical Trial (ANSWER). Available online: https://clinicaltrials.gov/study/NCT04544306 (accessed on 12 March 2025).
- Dworkin, R.; Sande, M.; Lee, B.; Chambers, H. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet 1989, 334, 1071–1073. [Google Scholar] [CrossRef]
- Heldman, A.W.; Hartert, T.V.; Ray, S.C.; Daoud, E.G.; Kowalski, T.E.; Pompili, V.J.; Sisson, S.D.; Tidmore, W.C.; Eigen, K.A.V.; Goodman, S.N.; et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy. Am. J. Med. 1996, 101, 68–76. [Google Scholar] [CrossRef]
- McCance-Katz, E.F.; Moody, D.E.; Prathikanti, S.; Friedland, G.; Rainey, P.M. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend. 2011, 118, 326–334. [Google Scholar] [CrossRef]
- Dedicoat, M.J. Rifampicin reduces methadone concentrations. BMJ 2012, 344, e4199. [Google Scholar] [CrossRef]
- Bupha-Intr, O.; Blackmore, T.; Bloomfield, M. Efficacy of early oral switch with β-lactams for low-risk Staphylococcus aureus Bacteremia. Antimicrob. Agents Chemother. 2020, 64, e02345-19. [Google Scholar] [CrossRef]
- Billington, M. Addiction Medicine’ in EMRA Fellowship Guide, Opportunities for Emergency Physicians, 2nd ed.; Emergency Medicine Residents Association: Irving, TX, USA, 2018. [Google Scholar]
- Atkinson, T.; Gulum, A.; Forkum, W. The future of pain pharmacy: Driven by need. Integr. Pharm. Res. Pract. 2016, 5, 33–42. [Google Scholar] [CrossRef]
- HHS Expands Access to Treatment for Opioid Use Disorder. U.S. Department of Health and Human Services; 2021. Available online: https://www.hhs.gov/about/news/2021/01/14/hhs-expands-access-to-treatment-for-opioid-use-disorder.html (accessed on 28 May 2021).
Drug | Dosing Recommendations | Duration of Therapy | Reference |
---|---|---|---|
Oritavancin | 1200 mg IV once | 7 days | [55] |
1200 mg IV every 48 h × 3 doses, followed by 1200 mg weekly | Weekly * | [51] | |
1200 mg IV every week | Weekly * | [53,54] | |
1200 mg IV on week 1, followed by 800 mg IV weekly | Weekly * | [57,58] | |
1500 mg IV once | 14 days | [59] | |
Dalbavancin | 1000 mg IV followed by 500 mg weekly, one week later | Weekly * | [60] |
1500 mg IV followed by 1000 mg every other week, two weeks later | 2 weeks ** | [59,61,62] | |
1000 mg IV every 14 days | Weekly * | [59] | |
1500 mg IV followed by 1500 mg 8 days after | 42 days | [59] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lorenzo, M.P.; Adams, K.K.; Housman, S.T. Common Bacterial Infections in Persons Who Inject Drugs. Medicines 2025, 12, 8. https://doi.org/10.3390/medicines12020008
Lorenzo MP, Adams KK, Housman ST. Common Bacterial Infections in Persons Who Inject Drugs. Medicines. 2025; 12(2):8. https://doi.org/10.3390/medicines12020008
Chicago/Turabian StyleLorenzo, Michael P., Kathleen K. Adams, and Seth T. Housman. 2025. "Common Bacterial Infections in Persons Who Inject Drugs" Medicines 12, no. 2: 8. https://doi.org/10.3390/medicines12020008
APA StyleLorenzo, M. P., Adams, K. K., & Housman, S. T. (2025). Common Bacterial Infections in Persons Who Inject Drugs. Medicines, 12(2), 8. https://doi.org/10.3390/medicines12020008